Mesh : Angiogenesis Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Axitinib Bevacizumab / administration & dosage Carcinoma, Renal Cell / drug therapy secondary Everolimus / therapeutic use Humans Imidazoles / therapeutic use Indazoles / therapeutic use Indoles / therapeutic use Interferon-alpha / administration & dosage Interleukin-2 / therapeutic use Kidney Neoplasms / pathology surgery Nephrectomy Niacinamide / analogs & derivatives therapeutic use Phenylurea Compounds / therapeutic use Pyrimidines / therapeutic use Pyrroles / therapeutic use Singapore Sirolimus / analogs & derivatives therapeutic use Sorafenib Sulfonamides / therapeutic use Sunitinib

来  源:   DOI:

Abstract:
BACKGROUND: The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC).
METHODS: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.
RESULTS: Six international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2014), the European Association for Urology (2013), the European Society of Medical Oncology (2012), the National Institute of Health and Clinical Excellence (2011), the Canadian Kidney Cancer Forum (2013) and the Asian Oncology Summit (2012). Recommendations on the first-, second- and third-line treatment for mRCC were developed.
CONCLUSIONS: These adapted guidelines form the SCAN Guidelines 2015 for systemic therapy of mRCC.
摘要:
暂无翻译
公众号